Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANTON LEE DUKE

Allopathic & Osteopathic Physicians Pediatrics

NPI
1235108150
CMS profile
853486
Location
LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$153.22

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $153.22 8

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Corium, LLC $95.43 5
PFIZER INC. $36.02 2
Sobi, Inc $21.77 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANTON LEE DUKE

NPI 1235108150 · CMS profile ID 853486

Allopathic & Osteopathic Physicians / Pediatrics

LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235108150?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANTON LEE DUKE, NPI 1235108150, CMS profile ID 853486. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235108150?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ANTON LEE DUKE, NPI 1235108150, CMS profile ID 853486. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235108150?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ANTON LEE DUKE, NPI 1235108150, CMS profile ID 853486, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1235108150?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $153.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Corium, LLC $22.2211/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924809179 CMS
Corium, LLC $15.7411/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924809181 CMS
Corium, LLC $12.3510/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924809177 CMS
PFIZER INC. $18.5309/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949322817 CMS
Sobi, Inc $21.7708/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940365395 CMS
Corium, LLC $22.3207/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924809175 CMS
Corium, LLC $22.8005/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924809173 CMS
PFIZER INC. $17.4904/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949135105 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $107.73 7
PY2020 $13.83 1
PY2022 $153.22 8
PY2023 $73.99 5
PY2024 $55.65 3
PY2025 $38.48 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $62,873.99 1
PY2025 Principal investigator $4,783.76 5
PY2024 Recipient $266,973.11 1
PY2024 Principal investigator $78,051.13 417
PY2023 Principal investigator $100,958.30 218
PY2022 Principal investigator $51,887.94 40
PY2021 Principal investigator $22,703.72 8
PY2020 Principal investigator $245,184.29 32
PY2019 Principal investigator $95,542.65 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

218 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575065
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575067
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575069
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575073
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575075
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575077
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575079
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575081
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575083
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575085
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575087
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575089
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575091
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575093
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575095
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575097
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575099
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575101
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575103
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575105
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575107
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575109
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575111
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575113
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575117
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575119
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575121
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575123
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575125
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575127
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575129
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575131
Principal investigator 1 Dermavant Sciences, Inc. $47.25 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575133
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575135
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575137
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575139
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575141
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575143
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575145
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575147
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575149
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575151
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575153
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575155
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575157
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575159
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575161
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575163
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575165
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575167
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575169
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575171
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575173
Principal investigator 1 Dermavant Sciences, Inc. $200.06 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575175
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575177
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575179
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575181
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575183
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575185
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575187
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575189
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575191
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575193
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575195
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575197
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575199
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575201
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575203
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575205
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575207
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575209
Principal investigator 1 Dermavant Sciences, Inc. $187.69 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575211
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575489
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575493
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575495
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575497
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575499
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575501
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575503
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575505
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575507
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575509
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575511
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575515
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575517
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575519
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575521
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575523
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575525
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575527
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575529
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575531
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575533
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575537
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575539
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575541
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575543
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575545
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575547
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575553
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575555
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575557
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575559
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575563
Principal investigator 1 Dermavant Sciences, Inc. $153.94 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575567
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575569
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575571
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575573
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575575
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575577
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575579
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575581
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575583
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575587
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575589
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575591
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575593
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575595
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575597
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575599
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575601
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575603
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575605
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575609
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575611
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575613
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575615
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575617
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575619
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575621
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575623
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575625
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575627
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575631
Principal investigator 1 Dermavant Sciences, Inc. $180.19 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575633
Principal investigator 1 Dermavant Sciences, Inc. $142.12 12/02/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993575635
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 11/30/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570713
Principal investigator 1 Dermavant Sciences, Inc. $872.31 11/30/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570715
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 11/01/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568603
Principal investigator 1 Dermavant Sciences, Inc. $871.25 11/01/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568605
Principal investigator 1 ABBVIE INC. $1,923.75 10/12/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998404001
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567741
Principal investigator 1 Dermavant Sciences, Inc. $872.31 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567743
Principal investigator 1 Dermavant Sciences, Inc. $872.31 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567745
Principal investigator 1 Dermavant Sciences, Inc. $872.31 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567747
Principal investigator 1 Dermavant Sciences, Inc. $872.31 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567751
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567753
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567755
Principal investigator 1 Dermavant Sciences, Inc. $871.25 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567757
Principal investigator 1 Dermavant Sciences, Inc. $871.25 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567759
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567761
Principal investigator 1 Dermavant Sciences, Inc. $872.31 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567763
Principal investigator 1 GlaxoSmithKline, LLC. $161.74 10/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127785371
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 09/13/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564013
Principal investigator 1 Dermavant Sciences, Inc. $872.31 08/26/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563571
Principal investigator 1 Dermavant Sciences, Inc. $872.31 08/26/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563573
Principal investigator 1 Dermavant Sciences, Inc. $872.31 08/26/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563575
Principal investigator 1 GlaxoSmithKline, LLC. $2,612.15 08/18/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127785373
Principal investigator 1 GlaxoSmithKline, LLC. $3,924.18 08/16/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127785369
Principal investigator 1 ABBVIE INC. $244.38 08/10/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998394961
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 07/15/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993560187
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 07/15/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993560189
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 07/15/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993560191
Principal investigator 1 Dermavant Sciences, Inc. $872.31 07/15/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993560193
Principal investigator 1 Dermavant Sciences, Inc. $872.31 07/15/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993560195
Principal investigator 1 Dermavant Sciences, Inc. $872.31 06/13/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559203
Principal investigator 1 Dermavant Sciences, Inc. $872.31 06/13/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559205
Principal investigator 1 Dermavant Sciences, Inc. $872.31 06/13/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559207
Principal investigator 1 Dermavant Sciences, Inc. $872.31 06/13/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559209
Principal investigator 1 Dermavant Sciences, Inc. $872.31 05/20/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558069
Principal investigator 1 Dermavant Sciences, Inc. $872.31 05/20/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558071
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 05/20/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558073
Principal investigator 1 Dermavant Sciences, Inc. $872.31 05/20/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558075
Principal investigator 1 Dermavant Sciences, Inc. $872.31 05/20/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558077
Principal investigator 1 ABBVIE INC. $2,243.75 05/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998382943
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555685
Principal investigator 1 Dermavant Sciences, Inc. $190.72 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555687
Principal investigator 1 Dermavant Sciences, Inc. $842.56 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555689
Principal investigator 1 Dermavant Sciences, Inc. $872.31 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555691
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555693
Principal investigator 1 Dermavant Sciences, Inc. $872.31 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555695
Principal investigator 1 Dermavant Sciences, Inc. $872.31 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555697
Principal investigator 1 Dermavant Sciences, Inc. $872.31 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555699
Principal investigator 1 Dermavant Sciences, Inc. $872.31 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555701
Principal investigator 1 Dermavant Sciences, Inc. $872.31 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555703
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555705
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 04/14/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555707
Principal investigator 1 Dermavant Sciences, Inc. $267.75 04/07/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553745
Principal investigator 1 Dermavant Sciences, Inc. $267.75 04/07/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553747
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 04/07/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553749
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 04/07/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993553751
Principal investigator 1 Dermavant Sciences, Inc. $1,133.69 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551121
Principal investigator 1 Dermavant Sciences, Inc. $1,063.56 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551123
Principal investigator 1 Dermavant Sciences, Inc. $872.31 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551125
Principal investigator 1 Dermavant Sciences, Inc. $872.31 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551127
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551129
Principal investigator 1 Dermavant Sciences, Inc. $805.38 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551131
Principal investigator 1 Dermavant Sciences, Inc. $872.31 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552483
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552485
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552487
Principal investigator 1 Dermavant Sciences, Inc. $871.25 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552489
Principal investigator 1 Dermavant Sciences, Inc. $871.25 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552491
Principal investigator 1 Dermavant Sciences, Inc. $872.31 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552493
Principal investigator 1 Dermavant Sciences, Inc. $872.31 02/17/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552495
Principal investigator 1 GlaxoSmithKline, LLC. $350.15 02/10/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006138815
Principal investigator 1 Dermavant Sciences, Inc. $3,000.00 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549729
Principal investigator 1 Dermavant Sciences, Inc. $267.75 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549731
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549733
Principal investigator 1 Dermavant Sciences, Inc. $190.72 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550537
Principal investigator 1 Dermavant Sciences, Inc. $842.56 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550539
Principal investigator 1 Dermavant Sciences, Inc. $872.31 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550541
Principal investigator 1 Dermavant Sciences, Inc. $872.31 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550543
Principal investigator 1 Dermavant Sciences, Inc. $871.25 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550545
Principal investigator 1 Dermavant Sciences, Inc. $872.31 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550547
Principal investigator 1 Dermavant Sciences, Inc. $872.31 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550549
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550551
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 01/11/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550553
Principal investigator 1 ABBVIE INC. $2,243.75 01/04/2023 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998363741